Clinical Trial Update: NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

View source ↗

Summary

Clinical trial update on a study evaluating nab-paclitaxel with or without serplulimab for early-stage HR+/HER2-negative breast cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Serplulimab (serplulimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer Invasive | Status: RECRUITING